Clearance of activated stellate cells for hepatic fibrosis regression: Molecular basis and translational potential

Biomedicine and Pharmacotherapy

Volumn 67, Issue 3, 2013, Pages 246-250

  Kong, Desong ^a   Zhang, Feng ^a   Zhang, Zili ^a   Lu, Yin ^a   Zheng, Shizhong ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Apoptosis; Hepatic fibrosis; Hepatic stellate cell; Immune clearance; Phenotype reversion; Senescence

Indexed keywords

DICKKOPF 1 PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; NATURAL KILLER CELL RECEPTOR NKG2D; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CELL FUNCTION; CELL PROLIFERATION; CYTOKINE RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOCOMPETENT CELL; LIVER FIBROSIS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; REVIEW; SENESCENCE; STELLATE CELL;

ANIMALS; CELL MIGRATION INHIBITION; GENETIC THERAPY; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; PROTEIN BIOSYNTHESIS;

EID: 84875544700     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.10.002     Document Type: Review

References (64)

1. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
2. Soares J.B., Pimentel-Nunes P., Afonso L., et al. Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. Innate Immun 2012, [Epub ahead of print]. 10.1177/1753425912436762.
3. Anthony B., Allen J.T., Li Y.S., McManus D.P. Hepatic stellate cells and parasite-induced liver fibrosis. Parasi Vectors 2010, 3:60.
4. Otogawa K., Ogawa T., Shiga R., Ikeda K., Kawada N. Induction of tropomyosin during hepatic stellate cell activation and the progression of liver fibrosis. Hepatol Int 2009, 3:378-383.
5. Iredale J.P. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001, 21:427-436.
6. Domitrović R., Jakovac H., Tomac J., Sain I. Liver fibrosis in mice induced by carbon tetrachloride and its reversion by luteolin. Toxicol Appl Pharmacol 2009, 241:311-321.
7. Suárez-Cuenca J.A., Chagoya de Sánchez V., Aranda-Fraustro A., et al. Partial hepatectomy-induced regeneration accelerates reversion of liver fibrosis involving participation of hepatic stellate cells. Exp Biol Med (Maywood) 2008, 233:827-839.
8. Gonzalez S.A., Fiel M.I., Sauk J., et al. Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection. J Viral Hepat 2009, 16:141-148.
9. Kumar A., Sinha R.A., Tiwari M., et al. Hyperthyroidism induces apoptosis in rat liver through activation of death receptor-mediated pathways. J Hepatol 2007, 46:888-898.
10. Lin H.J., Tseng C.P., Lin C.F., et al. A Chinese herbal decoction, Modified Yi Guan Jian induces apoptosis in hepatic stellate cells through an ROS-mediated mitochondrial/caspase pathway. Evid Based Complement Alternat Med 2011, 2011:459-531.
11. Schinoni M.I., Parana R. Apoptosis and progression of hepatic fibrosis in liver diseases. Acta Gastroenterol Latinoam 2006, 36:211-217.
12. Asai K., Tamakawa S., Yamamoto M., et al. Activated hepatic stellate cells overexpress p75NTR after partial hepatectomy and undergo apoptosis on nerve growth factor stimulation. Liver Int 2006, 26:595-603.
13. Iwamoto H., Sakai H., Tada S., et al. Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion. J Lab Clin Med 1999, 134:83-89.
14. Oakley F., Meso M., Iredale J.P., et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 2005, 128:108-120.
15. Ikeda H., Nagashima K., Yanase M., et al. Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2003, 285:G880-G886.
16. Zheng S., Chen A. Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J 2004, 384:149-157.
17. Cheng J.H., She H., Han Y.P., Wnt antagonism inhibits hepatic stellate cell activation, liver fibrosis., Am J, et al. Physiol Gastrointest Liver Physiol 2008, 294:G39-G49.
18. Duffield J.S., Forbes S.J., Constandinou C.M., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005, 115:56-65.
19. Radaeva S., Sun R., Jaruga B., et al. Naturalkiller cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis inducing ligand-dependent manners. Gastroenterology 2006, 130:435-452.
20. Melhem A., Muhanna N., Bishara A., et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006, 45:60-71.
21. Jeong W.I., Park O., Radaeva S., Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 2006, 44:1441-1451.
22. Friedman S.L. Mac the knife? Macrophages - the double-edged sword of hepatic fibrosis. J Clin Invest 2005, 115:29-32.
23. Liu C., Tao Q., Sun M., et al. Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. Lab Invest 2010, 90:1805-1816.
24. Fischer R., Cariers A., Reinehr R., Häussinger D. Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology 2002, 123:845-861.
25. Tang X., Yang J., Li J. Accelerative effect of leflunomide on recovery from hepatic fibrosis involves TRAIL-mediated hepatic stellate cell apoptosis. Life Sci 2009, 84:552-557.
26. Bansal R., Post E., Proost J.H., et al. PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis. J Control Release 2011, 154:233-240.
27. Hung K.S., Lee T.H., Chou W.Y., et al. Interleukin-10 gene therapy reverses thioacetamide-induced liver fi{ligature}brosis in mice. Biochem Biophys Res Commun 2005, 336:324-331.
28. Krishnadas D.K., Li W., Kumar R., et al. In vitro activation and differentiation of naive CD4+ and CD8+ T cells into HCV core- and NS3-specific armed effector cells: a new role for CD4+ T cells. Cell Immunol 2009, 259:141-149.
29. Bonilla N., Barget N., Andrieu M., et al. Interferon gamma-secreting HCV-specific CD8+ T cells in the liver of patients with chronic C hepatitis: relation to liver fibrosis - ANRS HC EP07 study. J Viral Hepat 2006, 13:474-481.
30. Jiang G., Yang H.R., Wang L., et al. Hepatic stellate cells preferentially expand allogeneic CD4+ CD25+ FoxP3+ regulatory T cells in an IL-2-dependent manner. Transplantation 2008, 86:1492-1502.
31. Notas G., Kisseleva T., Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol 2009, 130:16-26.
32. Park O., Jeong W.I., Wang L., et al. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 2009, 49:1683-1694.
33. Senoo H., Yoshikawa K., Morii M., et al. Hepatic stellate cell (vitamin A-storing cell) and its relative - past, present and future. Cell Biol Int 2010, 34:1247-1272.
34. Tsukamoto H. Adipogenic phenotype of hepatic stellate cells. Alcohol Clin Exp Res 2005, 29:132S-133S.
35. Kisseleva T., Cong M., Paik Y., et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A 2012, 109:9448-9453.
36. Tsukamoto H., She H., Hazra S., et al. Fat paradox of steatohepatitis. J Gastroenterol Hepatol 2008, 23:S104-S107.
37. Zhang F., Lu Y., Zheng S. Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis. Cell Signal 2012, 24:596-605.
38. She H., Xiong S., Hazra S., Tsukamoto H., et al. Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 2005, 280:4959-4967.
39. Klingbeil P., Isacke C.M. The " alternative" EMT switch. Breast Cancer Res 2011, 13:313.
40. Ikegami T., Zhang Y., Matsuzaki Y. Liver fibrosis: possible involvement of EMT. Cells Tissues Organs 2007, 185:213-221.
41. Yang L., Jung Y., Omenetti A., et al. Fate-mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers. Stem Cells 2008, 26:2104-2113.
42. Zeisberg M., Shah A.A., Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 2005, 280:8094-8100.
43. Vincan E., Barker N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis 2008, 25:657-663.
44. Chaffer C.L., Thompson E.W., Williams E.D. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 2007, 185:7-19.
45. Bullock M.D., Sayan A.E., Packham G.K., Mirnezami A.H. MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol Cell 2012, 104:3-12.
46. Yang C., Zeisberg M., Mosterman B., et al. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 2003, 124:147-159.
47. Friedman S.L., Roll F.J., Boyles J., et al. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. J Biol Chem 1989, 264:10756-10762.
48. Gaça M.D., Zhou X., Issa R., et al. Basement membrane-like matrix inhibits proliferation and collagen synthesis by activated rat hepatic stellate cells: evidence for matrix-dependent deactivation of stellate cells. Matrix Biol 2003, 22:229-239.
49. Huang G., Brigstock D.R. Integrin expression and function in the response of primary culture hepatic stellate cells to connective tissue growth factor (CCN2). J Cell Mol Med 2011, 15:1087-1095.
50. Yoshimoto N., Togo S., Kubota T., et al. Role of transforming growth factor-beta1 (TGF-beta1) in endotoxin-induced hepatic failure after extensive hepatectomy in rats. J Endotoxin Res 2005, 11:33-39.
51. Kato R., Kamiya S., Ueki M., et al. The fibronectin-derived antiadhesive peptides suppress the myofibroblastic conversion of rat hepatic stellate cells. Exp Cell Res 2001, 265:54-63.
52. Issa R., Zhou X., Constandinou C.M., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004, 126:1795-1808.
53. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
54. Sekoguchi S., Nakajima T., Moriguchi M., et al. Role of cell-cycle turnover and oxidative stress in telomere shortening and cellular senescence in patients with chronic hepatitis C. J Gastroenterol Hepatol 2006, 22:182-190.
55. Jun J.I., Lau L.F. Cellular senescence controls fibrosis in wound healing. Aging 2010, 2:627-631.
56. Krizhanovsky V., Yon M., Dickins R.A., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008, 134:657-667.
57. Kong X., Feng D., Wang H., et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis. Hepatology 2012, [Epub ahead of print]. 10.1002/hep.25744.
58. Kuilman T., Michaloglou C., Vredeveld L.C., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
59. Risques R.A., Lai L.A., Himmetoglu C., et al. Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res 2011, 71:1669-1679.
60. Cales P., Boursier J., Chaigneau J., et al. Treatment of liver fibrosis: clinical aspects. Gastroenterol Clin Biol 2009, 33:958-966.
61. Pinzani M., Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 2004, 36:231-242.
62. Seto W.K., Lee C.F., Lai C.L., et al. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One 2011, 6:e23077.
63. Wasmuth H.E., Tacke F., Trautwein C. Chemokines in liver inflammation and fibrosis. Semin Liver Dis 2010, 30:215-225.
64. Moreno M., Gonzalo T., Kok R.J., et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010, 51:942-952.